Latest News and Press Releases

STAR-LLD, a continuous delivery system of lenalidomide in development by Starton Therapeutics, was recently evaluated in a preclinical efficacy study in a lenalidomide-resistant animal model.The study...

STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a 90% lower CMax, a 70% lower AUC, and sustained Cmin...

Independent safety review approved dose escalation and initiation of third and final dosing cohortSTAR-LLD well tolerated in all subjects dosed to datePhase 1b/2 in newly diagnosed multiple myeloma...

Independent safety review approved dose escalation and initiation of next dosing cohortSTAR-LLD generally well tolerated in all subjects dosed to dateOn track to complete dosing of all cohorts in May...

The open-label, randomized, crossover, ascending dose study will assess STAR-LLD safety, tolerability, and pharmacokinetics in healthy subjects On track to complete dosing in May 2022 PARAMUS, N.J.,...

PARAMUS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary continuous delivery...

STAR-LLD is believed to be the first continuously delivered immunomodulatory imide drug (IMiD) in development to expand the use of lenalidomide in multiple myeloma and become the first IMiD for...

STAR-LLD is the first continuous delivery immunomodulatory drug (IMiD) in development to expand the use of lenalidomide in multiple myeloma and become the first IMiD for CLLOn track to complete...

PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...

PARAMUS, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies,...